医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promega GoTaq® Probe 1-Step RT-qPCR System Approved for Use in CDC’s COVID-19 Emergency Use Authorization Diagnostic Panel

2020年04月02日 AM04:55
このエントリーをはてなブックマークに追加


 

MADISON, Wis.

Promega Corporation’s GoTaq® Probe 1-Step RT-qPCR System is now in a Centers for Disease Control and Prevention COVID-19 diagnostic protocol for emergency use. The Promega tool is an approved master mix option for the CDC’s 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel that is available through the CDC’s Emergency Use Authorization (EUA). In a letter dated March 30, 2020, the FDA granted approval of an amendment to the CDC’s diagnostic COVID-19 assay that includes acknowledgement that Promega master mix is an approved amplification reagent for laboratories using the CDC’s assay. The assay protocol is used by hundreds of public health labs and clinical testing labs in the United States and is referenced by thousands of labs around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200401005732/en/

The Promega GoTaq® Probe 1-Step RT-qPCR System is now a recommended master mix option for the Centers for Disease Control and Prevention’s 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel that is available through the FDA’s Emergency Use Authorization. (Photo: Business Wire)

The Promega GoTaq® Probe 1-Step RT-qPCR System is now a recommended master mix option for the Centers for Disease Control and Prevention’s 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel that is available through the FDA’s Emergency Use Authorization. (Photo: Business Wire)

“Thanks to the CDC acting quickly to make product additions to their protocol, labs now have one more CDC-approved master mix when performing the 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel,” says Heather Tomlinson, Promega Director of Clinical Diagnostics. “The Promega GoTaq® Probe 1-Step RT-qPCR System expands the testing capacity in the US by being another option for labs to use for the amplification process in the CDC’s testing protocol.”

The GoTaq® Probe 1-Step RT-qPCR System is a ready-to-use master mix of optimized components for robust RT-qPCR using hydrolysis probes. Promega supplies automation, sample extraction and diagnostic reagents around the world, and began scaling up manufacturing in January to address unprecedented demand for COVID-19 related tools. Promega reagents are also currently incorporated in 15 COVID-19 diagnostic tests produced by other global diagnostic manufacturers.

For specific product details about the GoTaq® Probe 1-Step RT-qPCR System visit: www.promega.com/gotaqprobe

To learn more about Promega SARS-CoV-2 products and Promega technical support visit: www.promega.com/covid19

About Promega

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 4,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005732/en/

CONTACT

Penny Patterson

VP, Communications

Promega Corporation

Phone: (608) 274-4330

E-mail: penny.patterson@promega.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™